Call for papers: Monitoring disparities in prevention and treatment of HIV, viral hepatitis, STDs, and TB

The American Journal of Public Health and Centers for Disease Control and Prevention plan to publish a theme issue [including papers that] describe trends in health disparities in the United States…; describe, apply, or compare methods for measuring…differences in health outcomes or risk behaviors among the US population; or focus on metrics or methods for monitoring and interpreting temporal trends in health disparities. Authors should visit http://www.ajph.org for instructions.

Calling African Transgender Advocates: Apply for new AVAC program

[UPDATE: AVAC is no longer accepting applications.]

AVAC is pleased to announce a call for applications for participation in its inaugural PxROAR Transgender program, specifically for transgender and gender non-conforming HIV prevention advocates in Eastern and Southern Africa.

Application forms are available here. The submission deadline is 15 October.

About PxROAR Transgender Africa

PxROAR Transgender Africa will offer HIV prevention education and advocacy assistance with the goal of creating a regional agenda for HIV prevention research and implementation for the transgender community. The program is modeled on AVAC’s PxROAR Africa Program, which is tailored for key populations. Advocacy for self-determination and free expression is mutually dependent on the goal to seek control and, eventually, end HIV epidemics in underserved communities.

PxROAR Transgender Africa has two primary goals

1) To enhance awareness of and advocacy for biomedical HIV prevention.
2) To contribute to a transgender presence at country and regional level articulating a rights and biomedical prevention agenda.

Time commitments

The PxROAR Transgender Africa program is voluntary and intended to complement ongoing work in HIV, gender and/or human rights advocacy. The time commitment depends on your own level of availability. Outside of a required monthly group call, you determine your level of engagement. However, AVAC is interested in partnering with those who maximize the opportunity by tapping into all the program’s offerings. Technical and financial support is commensurate with level of commitment.

Who should apply?

  • Transgender and non-conforming African advocates from Eastern and Southern Africa interested in expanding their knowledge of biomedical HIV prevention research and implementation, creating a roadmap for transgender and HIV prevention research, translating scientific information and mobilizing communities toward the ultimate goal of controlling HIV in highly burdened, underserved populations.
  • Ideal candidates will have the potential to integrate their PxROAR advocacy, complementing and benefiting their current work.

Please send this request for applications to your relevant networks. If you have any questions, let us know at [email protected].

HIV Cure Research Strategy for Women: Where are we?

This blog post first appeared on Positively Aware. It represents a report taken from a session presentation summary at this year’s US Conference on AIDS (USCA), a community-based event which was held in September in Washington, DC.

The authors are Danielle Campbell, Julie Patterson, David Evans, Pedro Goicochea, Moisés Agosto, Dawn Averitt, Catalina Ramirez, and Karine Dubé Danielle Campbell, Julie Patterson, David Evans, Pedro Goicochea, Moisés Agosto, Dawn Averitt, Catalina Ramirez, and Karine Dubé.

The need for a cure is critical, but will the search for HIV cure strategies include women? Women are drastically underrepresented in HIV cure research studies. A review of 159 studies showed that only 18 percent of HIV cure study participants were women. Women have a high willingness to participate in research, although they are in general less willing than men to take risks related to HIV cure research interventions. Research is in the works to better understand the differences in willingness, but studies outside of the HIV cure arena suggest that if structural barriers to participation are diminished, and more effort is made to establish trusting relationships between investigators and participants, more women will participate.

Currently, there is no cure for HIV. Only one person has been cured, Timothy Ray Brown, after receiving two bone marrow transplants that simultaneously rid his body of HIV infected cells and gave him new cells that are resistant to HIV. Scientists are trying to replicate his cure. The transplant of stem cells is a central HIV cure strategy being investigated, particularly to eliminate nearly all traces of the virus from a person’s body (e.g., an eradicating, or sterilizing, cure). Other methods include the early administration of antiretroviral treatment, combined with a variety of strategies that make HIV more visible to infection-fighting immune cells, improving the immune system’s ability to detect and eliminate infected cells, and possibly rendering immune cells impervious to HIV infection.

Scientists suspect that there are gender-based differences that affect how these investigational interventions might work inside the body. For example, two studies have suggested that the presence of female hormones and hormone receptors on immune cells might make it more difficult to flush HIV out of hiding. In addition, cis-gender women who have female chromosomes are genetically primed for stronger immune responses to infection and to vaccines. They might, perhaps, have an advantage if vaccines or other approaches to prime the immune system’s response to HIV are used.

While studies of all diseases have traditionally lagged far behind in terms of participation by women, HIV has more recently had a better track record in terms of prevention and treatment trials, and improvements in recruitment and retention guided in part by the efforts of the Women’s Interagency HIV Study (WIHS), which is an NIH-funded cohort (or group) that studies the impact and progression of HIV infection among women in the United States. It is the largest and longest running HIV cohort focused on women. In total, 4,982 women at nine sites have participated in the cohort to date. The WIHS cohort is also uniquely diverse in that it is reflective of the US epidemic among women. The WIHS cohort is a great platform to advance HIV cure-related research in the United States. WIHS participants volunteer in studies that measure the HIV reservoir in the blood, genital tract, and other tissues, that study the role of sex hormones on HIV reservoirs and that examine the relationship with ART pharmacology.

The WIHS cohort has been creative in overcoming challenges to women’s participation in HIV cure research. For example, if women are asked to come in fasting for a lab test, the study site provides a substantive meal after the procedure. Providing mileage reimbursements, metro vouchers, and taxi rides are critically important, since transportation issues are a main deterrent to participation in research. Other strategies to improve sex equity in HIV cure-related research include addressing eligibility criteria, adapting recruitment strategies, and engaging community members as early as possible in the process. For this reason, WIHS could serve not only as a model for successful recruitment and retention of women living with HIV into research, but also as a source of participants who might be inspired to participate in HIV cure-oriented research.

Including women in HIV cure research means:

  • Thinking about what they need: different types of recruitment strategies and study coordination which may benefit from partnerships with different organizations or advocacy groups
  • Listening to what they want: information and a chance to participate, fair reimbursement and compensation, assistance with logistical barriers
  • Designing studies that reflect them: re-thinking eligibility criteria to balance participant risk with exclusions that disproportionally affect women
  • Prioritizing their involvement: a few women or a single study is not enough, we need to advocate for representation of all women, including transwomen

More Resources on Women and HIV Cure-Related Research

The Well Project/Women’s HIV/AIDS Research Initiative
The Well Project is a non-profit organization whose mission is to change the course of the HIV/AIDS pandemic through a unique and comprehensive focus on women and girls.

Treatment Action Group
A great resource for articles, reports and other information related to HIV cure research efforts.

Advocacy resources: treatmentactiongroup.org/CURE/advocacy

Media monitor which tracks cure research related news, places stories in context and addresses inaccuracies:
treatmentactiongroup.org/cure/media-monitor

A listing of clinical trials and observational studies related to the research effort to cure HIV infection:
treatmentactiongroup.org/cure/trials

AVAC
AVAC’s work includes a range of activities aimed at addressing: ethical issues, including community involvement in research; standards of prevention and care in trials; and community engagement and research literacy outside the context of a specific clinical trial or intervention.

HIV Cure Research Glossary
This glossary is designed for the media and laypersons interested in understanding the issues involved in HIV cure-related research.

CUREiculum
The CUREiculum is a suite of tools that provides simple, accessible information on HIV cure research, organizing into a systematic format for ongoing or issue-specific learning.

Social and Ethical Aspects of HIV Cure Research (searcHIV)
searcHIV is a multi-site, multi-disciplinary working group focusing on investigating the biosocial implications of HIV cure research.

Women’s Interagency HIV Study (WIHS)
The Women’s Interagency HIV Study (WIHS) is a large, comprehensive prospective cohort study designed to investigate the progression of HIV disease in women.

PrEP and Trial Design — A no brainer for some

Clinical trials for new HIV prevention methods offer participants counseling and access to the existing ways to protect oneself from HIV. It’s called the “standard of prevention” and is a package of prevention methods and services.

Now that oral PrEP is a proven HIV prevention method and WHO-recommended, some trials are adding it to the package. And that makes trials more complex. That’s a good problem to have, says Slim Abdool Karim, the director of the Centre for the AIDS Program of Research in South Africa, also known as CAPRISA. As the co-principal investigator of the landmark CAPRISA 004 tenofovir gel study and the recipient of multiple awards for his research, Karim brings incomparable perspective to this question. In this interview with AVAC’s Jeanne Baron, Karim talks about why designing trials with oral PrEP is a must—scientifically and ethically.

Listen here.

This interview is part of an ongoing series, and look out for our upcoming podcast—Px Pulse, which will feature interviews and discussions that explore vital topics in HIV Prevention research today. Tell us what you think!

Click on the links below to learn more about PrEP and standard of prevention in trials:

New Px Wire: PrEP, money and more

The latest issue of AVAC’s quarterly newsletter, Px Wire, is now available. Check it out for a deep dive into the data that suggest men who have sex with men may be protected by oral PrEP, even if they don’t dose every day—and for the reasons why these data do not apply to women. You’ll also find out why messages about global AIDS are on our mind—and what we’d change about the current global conversation.

Because money matters as much as messages, we’ve provided a centerspread that summarizes current investments, and trends over time, in HIV-prevention research and development. This full-color feature is excerpted from the recently-released report on HIV prevention research and development investment produced by AVAC and partners in the field.

Golden Age or Fools Gold?

Are we in the Golden Age of HIV prevention, as first heralded in Durban, South Africa at the 2016 International AIDS Society conference? Dr. Carl Dieffenbach is the Director of the Division of AIDS at the US National Institutes of Health, (NIH). He oversees one of the largest research budgets in the world for HIV.

In this interview with AVAC’s Jeanne Baron, Dr. Dieffenbach explains the recent progress and upcoming HIV prevention trials, and what it will take to “put out the fire.”

Check out this interview, our first in a series that preview our upcoming podcast — Px Pulse — which will feature interviews and discussions that explore vital topics in HIV Prevention research today.

Listen here.

Want to learn more about the research and trials Dr. Dieffenbach talks about? Follow these links:

On HVTN 702:
On Janssens’s Ad26 Mosaic program:
On HPTN 083 & 084:

Funding Opportunity: RFA-AI-17-028 Next Generation Multipurpose Prevention Technologies (NGM) (R61/R33 – Clinical Trials Optional)

NIAD and NIMH will be accepting applications to support the development of new and innovative multipurpose prevention technologies (MPTs) with the dual purpose of contraception and HIV prevention. Letters of Intent due 19 February 2018.

Informing the Research Enterprise: Webinar with Carl Dieffenbach on future priorities for HIV research networks

UPDATE: The webinar recording is now available: YouTube / Audio / Slides

Join a conversation with US government research leadership about the future of investments in the US National Institutes of Health’s (NIH) HIV clinical trial research networks in the US and internationally. Mark your calendar for Tuesday, September 5 at 2pm ET for a conversation with Dr. Carl Dieffenbach, the Director of the Division of AIDS (DAIDS) at the NIH’s National Institute of Allergy and Infectious Diseases.

Every seven years, the NIH reviews the structure and funding of its HIV clinical research networks. This “network recompetition” process involves decisions that will help determine the focus and priorities of its HIV clinical trial networks through 2027, as well as the number and structures of the various networks that undertake this research. These are critical questions for advocates to weigh in on—whether you are in the US or not.

The webinar will include a brief introductory presentation from Dr. Dieffenbach followed by a Q&A session. NIAID is also currently accepting public comments and questions online, so now is your chance!

Can’t make the webinar but have a question? Please send it on! We will also be scheduling a second webinar at a time more convenient for advocates outside of the US. And, as always, slides and a recording will be posted shortly after the conclusion of the webinar.

Special issue on Sexual and Reproductive Health and Rights Services and HIV: call for papers

You are invited to submit to a special supplement issue on the Integration of Sexual and Reproductive Health and Rights Services (SRHR) and HIV Prevention, Treatment, and Care Services across Sub-Saharan Africa. Selected papers will be published in BMC Infectious Diseases, BMC Public Health and Reproductive Health. Full details, including how to submit manuscripts, can be found here.

PrEP’s Entry into Kenya: Communities hold the key

On July 4, Kenyan civil society, including groups working on the frontlines of HIV prevention and treatment, called a meeting with the leaders and implementers of oral pre-exposure prophylaxis (PrEP) activities in the country. The meeting’s purpose was to have a frank discussion about the role of community support in the national PrEP program, and touch on progress with HIV self-testing implementation. Some of the civil society groups, like ISHTAR-MSM and Bar Hostess Empowerment Support Programme (BHESP), are also involved in implementation—they’ve partnered with Jilinde, a national-scale PrEP rollout project, or LVCT to help identify potential PrEP users, spread messages and deliver services.

Other CSOs in the room, such as Survivors, an NGO of female sex workers in Busia, Western Kenya, and the Kenya Legal & Ethical Issues Network on HIV and AIDS, aren’t delivering services, but, like BHESP and ISHTAR, represent advocates, activists and potential PrEP users. All were united by a common goal of shining a spotlight on community and civil society engagement as a critical link to successful PrEP rollout in the country.

In the months leading up to the May 4 launch of Kenya’s national program, many civil society groups gave inputs to the national PrEP technical working group (TWG), convened by the National AIDS & STI Control Program (NASCOP). This work is ongoing, with civil society represented on the various rollout committees.

But being invited to the table is not the same as setting the table—and at the July 4 meeting, the organizers structured a packed agenda in order to learn about progress and plans, as well as to express their views on priority issues.

Rosemary Mburu, Executive Director of WACI Health, and Nelson Otuoma, Executive Director of the National Empowerment Network of People living with HIV/AIDS in Kenya (NEPHAK), co-facilitated the meeting.

Mburu noted that many issues remain to be worked out if PrEP is to achieve its true potential in the country: communities need to be continuously informed and engaged; sustainable financing that includes domestic resources has to be secured; and county-level plans have to be designed, with appropriate material for use at the community level.

Otuoma, who recently won the inaugural Maisha Conference Award for his work in community advocacy, reminded everyone of PrEP’s massive potential in Kenya, but only “if we can overcome barriers like stigma.”

“Just like ARVs changed the face of HIV from a killer disease to a chronic condition, PrEP can help the country move further and faster along the HIV prevention roadmap,” he said.

Jointly presenting the viewpoint of young women to the convening, 24-year-olds Anastacia Kendi and Grace Kamau, part of the youth-serving group Sauti Skika, welcomed the launch of PrEP, calling it “an empowering tool to women and girls.”

“I hope there will be more investments in ensuring the interventions are made to work for women and girls’ needs alongside the needs of boys and men.”

Three established PrEP implementation projects in Kenya—the Partners Scale Up Project; Introducing PrEP in Combination Prevention (IPCP); and Bridge to Scale (also known as Jilinde, Kiswahili for “protect yourself”)—shared updates and lessons learned.

Speakers from these projects reported excitement about PrEP as a new prevention method in the country. Yet they said that there were obstacles when it comes to actual use. While there are reports of high demand in some communities and programs, there are also places where the number of people signing up to use PrEP is lower than the expected enrollment.

Adherence (taking the pill daily as prescribed) stands out as challenge; and many people who are using PrEP have been “lost to follow-up”, public-health lingo for a participant who starts taking a medication such as PrEP or antiretroviral treatment (for people living with HIV) but along the way stops returning for their monthly refill visits without informing their clinic.

In all updates, community engagement stood out as a critical part of the solution.

Dr Elizabeth Irungu, the director of the Partners Scale Up Project in Thika and Kisumu in central and western Kenya respectively, said the project team is finding broad acceptance for PrEP among heterosexual, HIV-serodiscordant couples.

“We now have something to give the HIV-negative person,” she stated.

Partners dispenses PrEP from Comprehensive Care Centres (CCCs), clinics that are primarily involved with HIV prevention and treatment.

“We think that by adding PrEP for HIV prevention for HIV-negative people, there may be a reduction of the stigma associated with going to CCCs, as both positive and negative people can get services there. However, there is a lot of work to be done to reduce stigma around HIV, and around going to a CCC,” said Irungu.

By June 2017 the project, funded by the Bill & Melinda Gates Foundation, had enrolled 290 couples. They hope to reach 4,800 couples by 2019—200 in each of 24 centers.

Jhpiego’s Jilinde project, also funded by the Gates Foundation, is working among men who have sex with men, sex workers and adolescent girls and young women at high risk for HIV.

Tom Marwa, Senior Technical Advisor at Jhpiego, informed the convening that 2,300 users were enrolled between February and June 2017 through 17 Jilinde PrEP delivery centres in 10 counties of Kenya. The program is on track to reach 20,000 PrEP users by 2020, and its experiences will contribute important lessons to other African countries planning to introduce PrEP, he added.

Introducing PrEP in Combination Prevention (IPCP) consortium, led by LVCT Health, is implementing PrEP among the same populations as Jilinde. The project started before the national launch of PrEP and was designed to test whether PrEP could be delivered to these populations from standard healthcare facilities.

Dr Michael Kiragu, who leads IPCP, said he was heartened to see good support of PrEP during the formative studies phase of the project. Yet out of a target of 2100, only 1626 PrEP users (77 percent of target) were enrolled and retained into the program. He said that this was a sign that there were barriers to PrEP uptake and use.

The project team has learned that an individual’s community has a huge influence on their decision-making, and stigma remains a barrier to PrEP uptake and adherence, he noted.

“PrEP users at IPCP clinics complain about the rattling of pills in the bottle, the color of the pill (blue), and about disapproval from their husbands, boyfriends or parents.” To address some of these challenges clinics have started giving out cotton balls to mute the rattling of pills, holding community dialogues on PrEP with men, and offering couples counseling. In addition, people using PrEP have pointed to support groups as one of the most important resources they depend on to help them maintain good adherence.

Dr Sarah Masyuko, NASCOP’s HIV testing and PrEP Manager, gave a keynote at the convening.

The first phase of communications and advocacy on PrEP had been hugely successful, she noted, with widespread media and social media engagement reaching all corners of the country. On the sustainability question raised by civil society, Dr Masyuko said the Ministry of Health is holding consultations with PEPFAR, The Global Fund, and private companies in Kenya to secure long-term financing for PrEP.

“PrEP rollout is unlike any other,” she noted, citing difficulties with gathering reliable data for an intervention that people can get on and off at will. She said the government is looking into an electronic system with unique identifiers that will help better track users nationwide. She challenged implementing partners to do even more to reach communities with accurate messages on PrEP and HIV self-testing, and that dispel rumours and misconceptions that stand in the way of uptake among eligble persons, defined in the Kenya national guidelines as anyone at substantial ongoing risk of HIV infection.

This background information provided the platform for a robust discussion of what’s working—and what else is needed. Civil society representatives were clear that PrEP messages needed to be highly tailored and that organizations with different positions in the communities needed to have the right infomation to deliver through trusted channels. This could mean fine-tuned messages that go beyond the category of “adolescent girl or young woman,” “sex worker,” or “MSM” to consider other life circumstances—how openly a person is living with his or her identity, their community support, their influencers, et cetera. Some of this work is underway; much more will come from civil society groups leading work on the ground and feeding back on what works and what doesn’t.

From the convening, Peter Mogere, lead pharmacist at the Partners Scale Up Project and 2017 AVAC Fellow, presented a 9-point list of ‘Civil Society Asks’ to the National Technical Working Group (TWG) on PrEP, on 7 July. Along with allocating domestic resources for PrEP, the asks focus on community engagement at the grassroots level; health care provider training; and combating human rights violations, stigma and discrimination.

Mogere said the TWG was highly receptive to the civil society asks; “The TWG Chair said she was looking forward to involving the civil society in reaching out to all communities that would benefit from PrEP. She noted that civil society works on the ground in all regions of the country, including rural areas, and reaching all people at risk of HIV infection is high on the priorities of the national PrEP program.”

As a next step, the advocates are planning to stay connected and to develop and advance priorities that they can pursue through meetings where civil society sets the agenda. The history of the epidemic tells us this is how things change.


AVAC provided technical and financial support for the convening, which was co-hosted by AVAC partners WACI Health and the National Empowerment Network of People living with HIV/AIDS in Kenya (NEPHAK), in collaboration civil society organizations ISHTAR-MSM; Survivors; International Network of religious leaders living with or personally affected by HIV (INERELA+)-Kenya; National Organization of Peer Educators (NOPE); I Choose Life; Health Gap; Bar Hostess and Empowerment Programme (BHESP); Keeping Alive Societies Hope (KASH); Persons Marginalized and Aggrieved (PEMA); Kenya Legal and Ethical Issues Network on HIV and AIDS (KELIN); and Sauti Skika, a project affiliated with NEPHAK.